Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Yael L. Maxwell

December 13, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

News Daily News

High Systolic BP, LDL at a Young Age Matter Later in Life

Caitlin E. Cox

December 26, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Michael O'Riordan

January 20, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

Advertisement

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Statins Are Cost-effective in the Elderly

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

High Systolic BP, LDL at a Young Age Matter Later in Life

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content